# CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

> **NCT04231851** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, Irvine** · enrollment: 30 (actual)

## Conditions studied

- Acute Myelogenous Leukemia (AML) Due to Therapy
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes

## Interventions

- **DRUG:** Glasdegib
- **DRUG:** CPX-351

## Key facts

- **NCT ID:** NCT04231851
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-19
- **Primary completion:** 2024-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04231851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04231851, "CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04231851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*